Format

Send to

Choose Destination
Br J Haematol. 2016 Nov;175(4):724-732. doi: 10.1111/bjh.14298. Epub 2016 Sep 8.

A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies.

Author information

1
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
2
Silver Lake Research Corporation, Azusa, CA, USA.

Abstract

Sickle cell disease (SCD) is a significant healthcare burden worldwide, but most affected individuals reside in low-resource areas where access to diagnostic testing may be limited. We developed and validated a rapid, inexpensive, disposable diagnostic test, the HemoTypeSC , based on novel monoclonal antibodies (MAbs) that differentiate normal adult haemoglobin (Hb A), sickle haemoglobin (Hb S) and haemoglobin C (Hb C). In competitive enzyme-linked immunosorbent assays, each MAb bound only its target with <0·1% cross-reactivity. With the HemoTypeSC test procedure, the sensitivity for each variant was <5·0 g/l. The accuracy of HemoTypeSC was evaluated on 100 whole blood samples from individuals with common relevant haemoglobin phenotypes, including normal (Hb AA, N = 20), carrier or trait (Hb AS, N = 22; Hb AC, N = 20), SCD (Hb SS, N = 22; Hb SC, N = 13), and Hb C disease (Hb CC, N = 3). The correct haemoglobin phenotype was identified in 100% of these samples. The accuracy of the test was not affected by Hb F (0-94·8% of total Hb) or Hb A2 (0-5·6% of total Hb). HemoTypeSC requires <1 μl of whole blood and no instruments or power sources. The total time-to-result is <20 min. HemoTypeSC may be a practical solution for point-of-care testing for SCD and carrier status in low-resource settings.

KEYWORDS:

haemoglobinopathy; lateral flow immunoassay; monoclonal antibody; point of care; sickle cell disease

PMID:
27605462
PMCID:
PMC5118141
DOI:
10.1111/bjh.14298
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center